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Novel ethyl 1,5-disubstituted-1H-pyrazole-3-carboxylates
as a new class of antimicrobial agents
A series of pyrazole derivatives 9–22 were designed and 
syn thesized. All the newly synthesized compounds were 
as sayed for their antimicrobial activity against the Gram-
positive bacteria Staphyllococcus aureus and Bacillius subtilis 
and the Gram-negative bacteria Escherichia coli, Pseudomo-
nas aeruginosa, in addition to the fungi organisms, Candida 
albicans, C. parapsilosis and C. tropicalis. Ethyl 5-(2,5-dimethyl-
thiophen-3-yl)-1-phenyl-1H-pyrazole-3-carboxylate (21) 
(MICE.coli = 0.038 µmol mL–1, MICP. aerug. = 0.067 µmol mL–1) is 
near ly as active as ampicillin (MIC = 0.033 and 0.067 
µmol mL–1), respectively. Ethyl 5-(4-bromo-2-chlorophenyl)-
1-phenyl-1H-pyrazole-3-carboxylate (16) (MIC = 0.015 
µmol mL–1) is more active than fluconazole (0.020 µmol mL–1) 
as a reference drug against C. parapsilosis.





Nitrogen heterocycles are of special interest because they constitute an important 
class of natural and non-natural products, many of which exhibit useful biological activi-
ties. Pyrazoles and their derivatives exhibit antimicrobial (1–3), anticancer (4), antiinflam-
matory (5) radioprotective (6), anticonvulsant (7) and antimalarial (8) activities. In the light 
of these facts, and as a continuation of our efforts towards synthesizing biologically active 
heterocyclic compounds (9–18), we aimed to prepare new derivatives of pyrazoles. The 
compounds were designed with the aim of exploring their antimicrobial activity and to 
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Melting points were uncorrected and determined on an electrothermal melting point 
apparatus (Stuart Scientific, UK). Precoated silica gel plates (Kieselgel 0.25 mm, 60G F254, 
Merck, Germany) were used for thin layer chromatography. Developing solvent system 
was composed of chloroform/methanol (8:2) and the spots were detected under UV. IR 
spectra (KBr discs) were recorded on a FT-IR spectrophotometer (Perkin Elmer, USA). 
NMR spectra were scanned on a NMR spectrophotometer (Bruker, Switzerland) operating 
at 500 MHz for 1H- and 125.76 MHz for 13C NMR. Chemical shifts are expressed in d-values 
(ppm) relative to TMS as an internal standard, using DMSO-d6 as a solvent. Elemental 
analyses were done on a model 2400 CHNSO analyzer (Perkin Elmer, USA). All reagents 
were purchased from Sigma (USA). Compounds 1 and 9 were prepared according to the 
reported methods (19, 20).
Synthesis of ethyl 4-(substituted phenyl)-2-hydroxy-4-oxobut-2-enoates (1–8)
Ethanol (100 mL) was converted to sodium ethoxide by portionwise addition of sodi-
um (0.46 g, 0.02 mol) before a solution of diethyl oxalate (2.92 g, 0.02 mol) and acetophenone 
derivative, namely, 4-chloroacetophenone, 3,4-dimethoxyacetophenone, 2,5-dimethoxy-
acetophenone, 2,5-dichloroacetophenone, 2-chloro-4-bromoacetophenone, 1-(naphthalene-
1-yl)ethanone, 1-(thiophen-2-yl)ethanone and/or 1-(2,5-dimethylthiophene-3-yl)ethanone 
(0.01 mol) in ethanol (50 mL) was added dropwise at 50 °C. The reaction mixture was 
heated under reflux for 2-3 h. After cooling the solvent was removed and the residue was 
taken up in water (200 mL) and acidified with concentrated HCl (1 mL). The aqueous mix-
ture was extracted with diethyl ether (3x150 mL). The combined extracts were washed with 
brine (100 mL), dried (MgSO4), and concentrated. The obtained solid was recrystallized 
from methanol to give compounds 1–8, respectively.
Synthesis of ethyl 1,5-disubstituted-1H-pyrazole-3-carboxylates (9–22)
A mixture of compound 1–8 (0.01 mol) with arylhydrazine derivative (0.012 mol) in 
ethanol (50 mL) was refluxed for 8 h. The reaction mixture was cooled and poured into ice 
water. The obtained solid was recrystallized from dioxane to give compounds 9–22, re-
spectively.
Physico-chemical, analytical and spectral data are displayed in Tables I and II. Syn-
thetic pathway is presented in Scheme 1.
Staphyloccocus aureus (NCTC-7447) and Bacillius subtilis (NCTC 1040) and Gram-nega-
tive bacteria E. coli (NCTC 10416), and Pseudomonas aeruginosa (ATCC 10145), in addition to 
the fungi organisms, Candida albicans (ATCC-10231), Candida parapsilosis (ATCC-22019) and 
Candida tropicalis (ATCC-66029) were tested. All microorganisms were purchased from 
American Type Culture Collection (Manassas, USA).
The antimicrobial activity screening of the newly synthesized compounds (9–22) was 
undertaken using the agar cup diffusion (8 mm diameter) assay I (21). The agar media were 
inoculated with test organisms and a solution of test compound 100 µg mL–1 in DMSO. 
Ampicillin (100 and 50 µg mL–1), and fluconazole (2 and 1 µg mL–1) were used as reference 
drugs for antibacterial and antifungal activity, respectively. The zones of inhibition were 
measured after 24 h of incubation.
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For determination of minimum inhibitory concentration (MIC) (21) by serial plate 
dilution method, five milligrams of each test compounds were dissolved in 1 mL of di-
methylsulfoxide (DMSO) separately to prepare stock solution. From stock solution serial 
dilutions were prepared. The plates were incubated at 37 °C for 24 h. MIC is the lowest 
concentration (µmol mL–1) of the test compound that resulted in no visible growth on the 
plates. DMSO was used as a solvent control to ensure that solvent had no effect on bacte-
rial growth. The results of the antimicrobial activities are summarized in Table III.
RESULTS AND DISCUSSION
Chemistry
b-Diketones 1–8 were prepared by Claisen reaction between acetophenone deriva-
tives and diethyl oxalate (Scheme 1). The synthesis of 1,5-diarylpyrazoles 9–22 was done 
by regioselective cyclization of arylhydrazines with b-diketones 1–8 in refluxing ethanol. 
Tables I and II show the physicochemical and the spectral data. The physicohemical data of 
compounds 1 and 9 are in accordance with those reported in the literature (19, 20). The struc-
tures of compounds 2–8 and 10–22 were confirmed by elemental analyses, IR, 1H NMR 
and 13C NMR spectral data. IR spectra of compounds 2–8 showed the presence of charac-
teristic bands for OH (3462–3421 cm–1), 2C=O (1751–1708 and 1685–1625 cm–1). 1H NMR 
spectra of compounds 2–8 revealed the presence of a triplet at 1.2–1.3 ppm assigned to CH3 





























9: Ar= C6H4Cl-4; X=H
10: Ar= C6H4Cl-4; X=Br
11: Ar= C6H3(OCH3)2-3,4; X=H
12: Ar= C6H3(OCH3)2-3,4; X=Br
13: Ar= C6H3(OCH3)2-2,5; X=H
14: Ar= C6H3(OCH3)2-2,5; X=Br
15: Ar= C6H3Cl2-2,5; X=H
16: Ar= C6H3Cl-2, Br-4; X=H
17: Ar= C6H3Cl-2, Br-4; X=Br
18: Ar= 1-naphthyl; X=H
19: Ar= 2-thienyl; X=H
20: Ar= 2-thienyl; X=Br
21: Ar= 3-thienyl-(CH3)2-2,5; X=H
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a molecular ion peak m/z at 280 (M+, 5.70 %) with a base peak at m/z 69 (100 %), and another 
significant peaks appeared at m/z 263 (30 %), 235 (21 %), 190 (12 %). IR spectra of 10–22 ex-
hibited the presence of bands at 1702–1739 cm–1 for C=O and at 1584–1604 cm–1 for C=N. 1H 
NMR spectra revealed the presence of a triplet at 1.1–1.6 ppm for CH3 ester and a quartet 
at 4.2 –4.5 ppm for CH2 ester. Mass spectrum of compound 14 showed a molecular ion peak 
m/z at 431 (M+, 9.25 %), 433 (M+ +2, 8.85 %) with a base peak at m/z 76 (100 %) in addition to 
























(280.27) 156–157 76 59.99/59.58 5.75/5.49 –
3 C6H3(OCH3)2-2,5 H
C14H16O6




78–79 88 49.85/49.63 3.49/3.16 –
5 C6H3Cl-2, Br-4 H
C12H10BrClO4 
(333.56)
90–91 65 43.21/43.46 3.02/3.25 –
6 1-naphthyl H C10H14O4 (270.28) 120–121 69 71.10/71.32 5.22/5.46 –
7 2-thienyl H C10H10O4S 
(226.25)












177–178 88 68.17/67.82 5.72/5.99 7.95/8.35
12 C6H3(OCH3)2-3,4 Br
C20H19BrN2O4 




156–157 75 68.17/68.51 5.72/5.49 7.95/7.66
14 C6H3(OCH3)2-2,5 Br
C20H19BrN2O4 
(431.28) 136–137 68 55.70/55.45 4.44/4.21 6.50/6.77
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(361.22) 153–154 73 59.85/59.53 3.91/3.65 7.76/7.48
16 C6H3Cl-2, Br-4 H
C18H14BrClN2O2 
(405.67)
> 300 70 53.29/53.56 3.48/3.18 6.91/6.68
17 C6H3Cl-2, Br-4 Br
C18H13Br2ClN2O2 
(481.90)
> 300 65 44.62/44.26 2.70/2.51 5.78/5.47
18 1-naphthyl H C22H18N2O2 
(341.39)
> 300 82 77.17/77.50 5.30/5.12 8.18/8.48
19 2-thienyl H C16H14N2O2S 
(298.36)
176–178 78 64.41/64.12 4.73/4.49 9.39/9.65
20 2-thienyl Br C16H13BrN2O2S (377.26) 110–111 86 50.94/50.69 3.47/3.72 7.43/7.19
21 3-thienyl-(CH3)2-2,5 H
C18H18N2O2S 




191–192 83 53.34/53.65 4.23/4.00 6.91/6.66









2 3421 (OH), 3083  
(CH arom.), 2939, 2836 
(CH aliph.), 1721, 1625  
(2C=O)
1.2 [t, 3H, CH3, J = 7.0 Hz], 3.9 [s, 6H, 2OCH3], 4.3 [q, 2H, 
CH2, J = 6.9 Hz], 6.9 [s, 1H, CH], 7.0-7.5 [m, 3H, Ar-H], 
15.3 [s, 1H, OH, D2O exchangeable]
14.1, 56.1(2), 62.5, 97.9, 109.9, 110.4, 122.8, 128.0, 149.3, 
154.1, 162.4, 167.2, 190.7
280 [M+], 
69 (100)
3 3426 (OH), 3098  
(CH arom.), 2953, 2840 
(CH aliph.), 1719, 1678  
(2C=O)
1.3 [t, 3H, CH3, J = 7.2 Hz], 3.8 [s, 6H, 2OCH3], 4.3 [q, 2H, 
CH2, J = 6.9 Hz], 7.1-7.3 [m, 4H, Ar-H + CH], 14.8 [s, 1H, 
OH, D2O exchangeable]
13.7, 56.0(2), 62.9, 113.2, 113.6, 114.2, 124.3, 125.2, 153.0, 




4 3421 (OH), 3100  
(CH arom.), 2939, 2876 
(CH aliph.), 1730, 1638  
(2C=O), 779 (C-Cl)
1.3 [t, 3H, CH3, J = 7.1 Hz], 4.3 [q, 2H, CH2, J = 7.2 Hz], 
6.8-7.5 [m, 4H, Ar-H + CH], 14.6 [s, 1H, OH, D2O 
exchangeable]




5 3421 (OH), 3100  
(CH arom.), 2950, 2860 
(CH aliph.), 1708, 1683  
(2C=O), 723 (C-Cl)
1.3 [t, 3H, CH3, J = 6.8 Hz], 4.1 [q, 2H, CH2, J = 7.0 Hz], 
6.7-8.0 [m, 4H, Ar-H + CH], 15.2 [s, 1H, OH, D2O 
exchangeable]
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6 3446 (OH), 3085  
(CH arom.), 2950, 2825 
(CH aliph.), 1743, 1654  
(2C=O)
1.3 [t, 3H, CH3, J = 7.1 Hz], 4.2 [q, 2H, CH2, J = 6.9 Hz], 
6.8-8.1 [m, 7H, Ar-H], 8.2 [s, 1H, CH], 15.1 [s, 1H, OH, 
D2O exchangeable]
13.8, 62.2, 102.6, 123.0, 127.1, 127.6, 128.9, 129.8, 130.1, 
132.1, 133.3, 134.1, 135.2, 161.7, 190.2, 198.2
270 [M+], 
54 (100)
7 3462 (OH), 3110  
(CH arom.), 2963, 2861 
(CH aliph.), 1751, 1685  
(2C=O)
1.3 [t, 3H, CH3, J = 6.9 Hz], 4.3 [q, 2H, CH2, J = 7.2 Hz], 
6.8-7.7 [m, 4H, Ar-H + CH], 14.8 [s, 1H, OH, D2O 
exchangeable]
13.7, 62.1, 97.9, 129.1, 130.3, 133.0, 139.0, 161.4, 168.9, 188.8 
226 [M+], 
69 (100)
8 3430 (OH), 3100  
(CH arom.), 2930, 2871 
(CH aliph.), 1708, 1641  
(2C=O)
1.3 [t, 3H, CH3, J = 7.3 Hz], 2.3 [s, 6H, 2CH3], 4.4 [q, 2H, 
CH2, J = 7.1 Hz], 6.6-8.0 [m, 2H, Ar-H + CH], 11.4 [s, 1H, 
OH, D2O exchangeable]




10 3098 (CH arom.), 2965, 
2861 (CH aliph.), 1714, 
(C=O), 1608 (C=N), 765 
(C-Cl)
1.3 [t, 3H, CH3, J = 7.6 Hz], 4.1 [q, 2H, CH2, J = 7.5 Hz], 
6.9-8.1 [m, 9H, Ar-H + CH pyrazole]
14.0, 63.2, 115.2, 120.8 (2), 126.1, 126.9 (2), 127.7, 128.6, 
129.6 (2), 130.6, 133.5, 138.1, 141.0, 144.1, 163.5 
403 [M+], 
78 (100)
11 3091 (CH arom.), 2982, 
2951 (CH aliph.), 1721, 
(C=O), 1589 (C=N)
1.1 [t, 3H, CH3, J = 7.6 Hz], 3.6 [s, 6H, 2OCH3], 4.2 [q, 2H, 
CH2, J = 7.4 Hz], 6.9-8.0 [m, 9H, Ar-H + CH pyrazole]
12.5, 56.4, 55.8, 63.2, 110.1, 112.1, 115.2, 116.8, 118.1, 123.1 
(2), 126.2, 128.6 (2), 140.4, 140.6, 146.8, 150.6, 151.3, 165.7 
352 [M+], 
77 (100)
12 3078 (CH arom.), 2950, 
2835 (CH aliph.), 1722, 
(C=O), 1610 (C=N)
1.4 [t, 3H, CH3, J = 7.3 Hz], 3.5 [s, 6H, 2 OCH3], 4.4 [q, 2H, 
CH2, J = 7.3 Hz], 6.9-8.1 [m, 9H, Ar-H + CH pyrazole]
14.2, 56.2, 56.3, 62.4, 111.6, 112.6, 114.6, 118.3, 119.7, 122.1, 
126.3 (2), 127.5 (2), 139.7, 139.8, 144.6, 151.5, 153.1, 164.2
431 (M+), 
42 (100)
13 3100 (CH arom.), 2948, 
2835 (CH aliph.), 1739, 
(C=O), 1584 (C=N)
1.3 [t, 3H, CH3, J = 7.1 Hz], 3.8 [s, 6H, 2OCH3], 4.4 [q, 2H, 
CH2, J = 7.2 Hz], 6.6-7.8 [m, 9H, Ar-H + CH pyrazole]
13.8, 55.2, 55.3, 62.9, 110.7, 111.5, 115.8, 116.3, 119.0, 123.7 
(2), 127.8, 128.4 (2), 140.0, 140.9, 144.2, 150.1, 152.8, 163.1 
352 [M+], 
59 (100)
14 3100 (CH arom.), 2978, 
2886 (CH aliph.), 1718, 
(C=O), 1602 (C=N)
1.1 [t, 3H, CH3, J = 7.5 Hz], 3.7 [s, 6H, 2 OCH3], 4.5 [q, 2H, 
CH2, J = 7.4 Hz], 6.7-7.5 [m, 9H, Ar-H + CH pyrazole]
13.8, 55.2, 55.3, 62.9, 110.7, 112.8, 115.8, 116.7, 119.0, 123.7, 
127.8 (2), 128.4 (2), 140.0, 140.9, 144.2, 150.1, 152.8, 163.1 
431 [M+], 
76 (100)
15 3095 (CH arom.), 2983, 
2872 (CH aliph.), 1702, 
(C=O), 1587 (C=N), 757 
(C-Cl)
1.2 [t, 3H, CH3, J = 7.2 Hz], 4.2 [q, 2H, CH2, J = 7.1 Hz], 
6.8-8.0 [m, 9H, Ar-H + CH pyrazole]
14.2, 62.9, 111.5, 121.7 (2), 124.3, 128.5, 129.5 (2), 130.2, 
130.4, 131.1, 131.8, 132.6, 136.4, 140.4, 143.4, 161.3
361 [M+], 
77 (100)
16 3098 (CH arom.), 2970, 
2836 (CH aliph.), 1708, 
(C=O), 1604 (C=N), 779 
(C-Cl)
1.1 [t, 3H, CH3, J = 7.4 Hz], 4.4 [q, 2H, CH2, J = 7.4 Hz], 
7.5-8.2 [m, 9H, Ar-H + CH pyrazole]
15.0, 64.8, 115.5, 117.9 (2), 126.8, 128.0, 129.0, 129.1 (2), 
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17 3060 (CH arom.), 2955, 
2866 (CH aliph.), 1704, 
(C=O), 1610 (C=N), 850 
(C-Cl)
1.2 [t, 3H, CH3, J = 7.3 Hz], 4.3 [q, 2H, CH2, J = 7.4 Hz], 
6.5-7.9 [m, 8H, Ar-H + CH pyrazole]
13.6, 62.4, 109.3, 120.3, 123.0 (2), 124.5, 128.4, 130.6, 131.0, 
134.0, 134.5, 135.1, 136.7, 138.2, 144.1, 144.5, 160.3
481 [M+], 
43 (100)
18 3053 (CH arom.), 2926, 
2843 (CH aliph.), 1700, 
(C=O), 1570 (C=N)
1.2 [t, 3H, CH3, J = 7.3 Hz], 4.3 [q, 2H, CH2, J = 7.3 Hz], 
6.9-8.0 [m, 13H, Ar-H + CH pyrazole]
13.8, 62.1, 102.6, 123.0 (2), 124.9, 126.6 (2), 127.1, 127.7, 




19 3100 (CH arom.), 2977, 
2862 (CH aliph.), 1728, 
(C=O), 1599 (C=N)
1.2 [t, 3H, CH3, J = 7.5 Hz], 4.3 [q, 2H, CH2, J = 7.3 Hz], 
6.4-7.9 [m, 9H, Ar-H + CH pyrazole]
13.7, 62.1, 111.6, 119.6, 121.4 (2), 128.2, 128.8, 129.1, 129.7, 
131.9 (2), 138.5, 140.0, 145.3, 163.4
298 [M+], 
77 (100)
20 3099 (CH arom.), 2981, 
2886 (CH aliph.), 1709, 
(C=O), 1590 (C=N)
1.2 [t, 3H, CH3, J = 7.2 Hz], 4.3 [q, 2H, CH2, J = 7.2 Hz], 
7.0-7.7 [m, 8H, Ar-H + CH pyrazole]
14.1, 60.6, 109.0, 122.7, 127.7 (2), 128.6, 128.7, 128.8, 131.5, 
132.3 (2), 137.9, 138.7, 143.4, 161.7
377 [M+], 
76 (100)
21 3085 (CH arom.), 2968, 
2840 (CH aliph.), 1710, 
(C=O), 1560 (C=N)
1.1 [t, 3H, CH3, J = 7.4 Hz], 2.5 [s, 6H, 2CH3], 4.4 [q, 2H, 
CH2, J = 7.5 Hz], 6.8-7.9 [m, 7H, Ar-H + CH pyrazole]
11.6, 14.5, 14.8, 62.6, 109.4, 120.8 (2), 123.0, 126.5, 127.1, 
128.0 (2), 134.5, 135.2, 136.8, 139.3, 144.4, 160.4
326 [M+], 
91 (100)
22 3098 (CH arom.), 2949, 
2871 (CH aliph.), 1708, 
(C=O), 1599 (C=N)
1.6 [t, 3H, CH3, J = 7.1 Hz], 2.6 [s, 6H, 2CH3], 4.5 [q, 2H, 
CH2, J = 7.1 Hz], 6.5-7.9 [m, 6H, Ar-H + CH pyrazole]
11.1, 13.9, 15.8, 57.4, 115.5, 121.3, 123.1 (2), 126.5, 127.1, 




Table III lists the results of the antimicrobial screening of the new compounds against 
some Gram-positive and some Gram-negative bacteria and fungi. The antibacterial screen-
ing revealed that compound 21 (MICE. coli = 0.038 µmol mL–1, MICP. aeruginosa = 0.076 µmol 
mL–1) is nearly as active as ampicillin (MICE. coli = 0.033, MICP. aeruginosa 0.067 µmol mL–1). The 
antifungal screening showed that compound 16 (MIC = 0.015 µmol mL–1) exhibited more 
potency activity than fluconazole (0.020 µmol mL–1) against C. parapsilosis. Also, compound 
16 showed lower activity than fluconazole (0.005 µmol mL–1) against C. albicans and C. tropi-
calis (MICC. albicans = 0.015 µmol mL–1, MICC. tropicalis = 0.030 µmol mL–1). From these results it 
was found that the presence of 2,5-dimethylthienyl moiety at 5-position and unsubsituted 
phenyl ring at 1-position in compound 21 enhanced the antibacterial activity against E. 
coli, while the presence of (un)substituted aromatic hydrocarbon moiety or unsubstituted 
thienyl at 5-position and (un)substituted phenyl ring at 1-position in compounds 9–20, 22 
revealed a moderate or weak activity. Dihalogenated phenyl at 5-position and unsubsti-
tuted phenyl at 1-position in compound 16 revealed significant activity compared with 
fluconazole as reference drug against C. parapsilosis. The remaining compounds were 
found either weak or inactive.
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  9 0.306 0.153 0.153 0.306 0.153 0.153 0.306
10 0.124 0.248 0.124 0.248 0.124 0.062 0.124
11 0.142 0.142 0.142 0.142 0.071 0.142 0.142
12 0.232 0.116 0.232 0.232 0.058 0.116 0.116
13 0.142 0.142 0.142 0.142 0.284 NA* NA
14 0.116 0.232 0.116 0.116 0.232 NA* NA
15 0.138 0.138 0.138 0.138  0.069 0.069 0.034
16 0.246 0.123 0.123 0.246 0.015 0.030 0.015
17 0.103 0.103 0.103 0.103 NA NA NA
18 0.293 NA 0.146 NA 0.293 0.293 0.293
19 NA 0.167 NA 0.325 0.167 0.167 0.167
20 NA NA 0.265 NA 0.132 0.132 0.132
21 0.076 0.076 0.038 0.076 NA 0.153 NA
22 0.123 0.246 0.123 0.123 0.061 0.061 NA
Ampicillin 0.033 0.008 0.033 0.067 NA 0.067 0.134
Fluconazole – – – – 0.005 0.005 0.020
NA – Compounds having MIC > 0.5 µmol mL–1.
CONCLUSIONS
This study showed that the newly synthesized ethyl 5-(2,5-dimethylthiophen-3-yl)-1-
phenyl-1H-pyrazole-3-carboxylate (21) was found to be of comparable activity as ampicil-
lin against E. coli and P. aeruginosa. The same is true for ethyl 5-(4-bromo-2-chlorophenyl)-
1-phenyl-1H-pyrazole-3-carboxylate (16) vs. fluconazole against Candida parapsilosis. This is 
due to the presence of dihalogenated phenyl at 5-position and unsubstituted phenyl at 
1-position of the pyrazole ring.
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